RxDoctor Payments Data

Jatinder Pruthi, MD

Gastroenterology · Lancaster, CANPI 1205852985

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $176,973 of the $216,983 with a category attached, or 81.6%. 39 manufacturers reported payments, led by AbbVie at 48.2% of the total. Reporting peaked in 2024 at $49,373 and has fallen 52.4% since, to $23,490 in 2025. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$216,983in general payments, 2019–2025

Across 1,055 payments — averaging $205.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$105K
  • Gilead$49K
  • Phathom Pharmaceuticals, Inc.$30K
  • Redhill Biopharma Inc.$7K
  • Ironwood Pharmaceuticals, Inc$4K
  • Mirum Pharmaceuticals, Inc.$4K
  • plus $19K from 33 others
$4,241,704in research payments, 2019–2025

Across 1,337 payments — averaging $3172.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$787K
  • Janssen Research & Development, LLC$501K
  • Bristol Myers Squibb$458K
  • Eli Lilly$417K
  • Pfizer$398K
  • Boehringer Ingelheim International GmbH$355K
  • plus $1.3M from 19 others

What the payments were for

  • Consulting fees$10,5855%
  • Speaking & faculty fees$176,97382%
  • Travel & lodging$9,4244%
  • Food & beverage$19,3339%
  • Education$6140%
  • Gifts$530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$216,983 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$781,696
Medicare patients
1,384
Services billed
7,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab20$534,985
LinzessLinaclotide288$331,819
RinvoqUpadacitinib15$110,862
IbsrelaTenapanor Hcl28$83,125
XifaxanRifaximin20$76,758
VoqueznaVonoprazan Fumarate53$62,337
TrulancePlecanatide67$55,329
RezdiffraResmetirom11$50,028
Sucralfate324$32,361
MovantikNaloxegol Oxalate51$32,267
Dexlansoprazole DrDexlansoprazole78$26,209
Budesonide ErBudesonide15$20,303
ViberziEluxadoline11$19,788
Pantoprazole Sodium1,274$18,313
Mesalamine ErMesalamine41$10,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,755$534,98520 claims
AbbVieLinzess, Rinvoq, Viberzi$104,511$462,469314 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$3,509$132,08787 claims
Ardelyx, Inc.Ibsrela$2,128$83,12528 claims
Phathom Pharmaceuticals, Inc.Voquezna$29,677$62,33753 claims
Madrigal PharmaceuticalsRezdiffra$544$50,02811 claims
Redhill Biopharma Inc.Movantik$7,048$32,26751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Lancaster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →